Frank Sands's RARE Position Overview
Frank Sands (via Sands Capital Management, LLC) currently holds 3.49 M shares of Ultragenyx Pharmaceutical Inc. (RARE) worth $80.17 M, representing 0.24% of the portfolio. First purchased in 2023-Q2, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Frank Sands has maintained a strategic position in RARE, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 1.54 M shares. Largest reduction occurred in Q4 2024, reducing 820,252 shares.
Analysis based on 13F filings available since 2013 Q2
Frank Sands's Ultragenyx Pharmaceutical (RARE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ultragenyx Pharmaceutical (RARE) Trades by Frank Sands
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -284,129 | Reduce 7.54% | 3.49 M | $23.00 |
| Q3 2025 | -173,632 | Reduce 4.40% | 3.77 M | $30.08 |
| Q2 2025 | -220,076 | Reduce 5.29% | 3.94 M | $36.36 |
| Q1 2025 | -134,442 | Reduce 3.13% | 4.16 M | $36.21 |
| Q4 2024 | -820,252 | Reduce 16.03% | 4.3 M | $42.07 |
| Q3 2024 | -236,495 | Reduce 4.42% | 5.12 M | $55.55 |
| Q2 2024 | +1.5 M | Add 38.74% | 5.35 M | $41.10 |
| Q1 2024 | -258,561 | Reduce 6.28% | 3.86 M | $46.69 |
| Q4 2023 | +1.54 M | Add 59.79% | 4.12 M | $47.82 |
| Q3 2023 | -96,421 | Reduce 3.61% | 2.58 M | $35.65 |
| Q2 2023 | +2.67 M | New Buy | 2.67 M | $46.13 |
Frank Sands's Ultragenyx Pharmaceutical Investment FAQs
Frank Sands first purchased Ultragenyx Pharmaceutical Inc. (RARE) in Q2 2023, acquiring 2,673,638 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Frank Sands has held Ultragenyx Pharmaceutical Inc. (RARE) for 11 quarters since Q2 2023.
Frank Sands's largest addition to Ultragenyx Pharmaceutical Inc. (RARE) was in Q2 2023, adding 2,673,638 shares worth $123.33 M.
According to the latest 13F filing for Q4 2025, Frank Sands's firm, Sands Capital Management, LLC, owns 3,485,724 shares of Ultragenyx Pharmaceutical Inc. (RARE), valued at approximately $80.17 M.
As of the Q4 2025 filing, Ultragenyx Pharmaceutical Inc. (RARE) represents approximately 0.24% of Frank Sands's publicly disclosed stock portfolio, making it one of their key holdings.
Frank Sands's peak holding in Ultragenyx Pharmaceutical Inc. (RARE) was 5,354,750 shares, as reported at the end of Q2 2024.